Article Text

Download PDFPDF
Surgical Treatment of Metastatic Ovarian Tumors From Extragenital Primary Sites
  1. Veysel Sal, MD,
  2. Fuat Demirkiran, MD,
  3. Samet Topuz, MD,
  4. Ilker Kahramanoglu, MD,
  5. Ibrahim Yalcin, MD,
  6. Tugan Bese, MD,
  7. Hamdullah Sozen, MD,
  8. Nedim Tokgozoglu, MD,
  9. Yavuz Salihoglu, MD,
  10. Hasan Turan, MD,
  11. Cem Iyibozkurt, MD,
  12. Tugba Kolomuc, MD,
  13. Nigar Sofiyeva, MD,
  14. Sinan Berkman, MD and
  15. Macit Arvas, MD
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul University Cerrahpasa Faculty of Medicine; and
  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
  1. Address correspondence and reprint requests to Ilker Kahramanoglu, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey. E-mail: ilkerkahramanoglu{at}hotmail.com.

Abstract

Objective The purpose of this study was to investigate the outcomes and prognostic factors of metastasectomy in patients with metastatic ovarian tumors from extragenital primary sites.

Materials and Methods All patients with pathologically confirmed metastatic ovarian tumors between January 1997 and June 2015 were included in this study. A total of 131 patients were identified. The data were obtained from the patients’ medical records. Clinicopathological features were evaluated by both univariate and multivariate analyses.

Results The primary sites were colorectal region (53.4%), stomach (26%), and breast (13%). Preoperative serum CA 125 and CA 19-9 levels were elevated in 29.4% and 39.8% of the patients, respectively. Cytoreductive surgery was performed in 41.2% of the patients. Seventy-three (55.7%) patients had no residual disease after surgery. Sixty-six (49.6%) patients had combined metastases at the time of the surgery to sites including the liver, pancreas, lung, bone, lymph nodes, bladder, or the intestine. With a median follow-up of 33 months, the median survival time was 22 months. The estimated 5-year survival probability is 0.26. On univariate analysis, primary cancer site, combined metastasis outside the ovaries, residual disease, preoperative serum CA 125 and CA 19-9 levels, and histologic type were significant parameters for overall survival. Furthermore, residual disease, preoperative serum CA 19-9 level, and primary cancer site were found to be independent prognostic factors on multivariate analysis.

Conclusions The most common primary sites for ovarian metastasis are gastrointestinal tract. Metastasectomy may have beneficial effects on survival, especially if the residual disease is less than 5 mm. Prospective studies warranted to evaluate the value of metastasectomy in patients with ovarian metastasis.

  • Ovarian cancer
  • Metastasectomy
  • Surgery
  • Survival

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • The authors declare no conflicts of interest.